Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate

被引:4
作者
Jann, MW
Wei, FC
Lin, HN
Ching, PC
Chang, WH
机构
[1] TAIPEI CITY PSYCHIAT CTR,LAB BIOL PSYCHIAT,TAIPEI 10510,TAIWAN
[2] MERCER UNIV,SO SCH PHARM,DEPT PHARM PRACTICE & PHARM SCI,ATLANTA,GA
[3] HUNG CHI PSYCHIAT HOSP,TAIPEI,TAIWAN
[4] NATL TAIWAN UNIV,TAIPEI 10764,TAIWAN
关键词
haloperidol; haloperidol decanoate; plasma concentrations; reduced haloperidol; reduced haloperidol/haloperidol ratios;
D O I
10.1016/0278-5846(95)00293-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
1. Haloperidol and reduced haloperidol plasma levels were measured in schizophrenic patients who received both oral (10 mg, 51-16 and 20 mg, N=4) and depot haloperidol treatment. 2. Patients were of Asian ethnicity and were safely and effectively converted from oral to depot therapy using a loading dose regimen using a 100 mg weekly injection interval for 4 weeks, biweekly for one month end then monthly. 3. Significant correlations were found for plasma haloperidol and reduced haloperidol levels and reduced haloperidol/haloperidol ratios between oral and depot therapy in these non-smoking patients. 4. A loading dose regimen is needed due to the long elimination half-life of decanoate of 26 days otherwise steady-state condition will not occur until 3-4 months of therapy. 5. Patients were maintained on monthly depot treatment for 40 weeks after the loading doss regimen and only one patient relapsed during treatment despite dosage Increases. 6. She formation of reduced haloperidol remained consistent for oral and depot haloperidol treatment.
引用
收藏
页码:73 / 86
页数:14
相关论文
共 27 条
[1]   HALOPERIDOL DECANOATE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN PSYCHOSIS [J].
BERESFORD, R ;
WARD, A .
DRUGS, 1987, 33 (01) :31-49
[2]   PROLONGED HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-CONCENTRATIONS AFTER DECANOATE WITHDRAWAL [J].
CHANG, WH ;
LIN, SK ;
JUANG, DJ ;
CHEN, LC ;
YANG, CH ;
HU, WH ;
CHIEN, CP ;
LAM, YWF ;
JANN, MW .
SCHIZOPHRENIA RESEARCH, 1993, 9 (01) :35-40
[3]  
CHANG WH, 1989, BIOL PSYCHIAT, V26, P239
[4]   DISPOSITION OF HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-LEVELS AFTER SINGLE-DOSE HALOPERIDOL DECANOATE ADMINISTRATION [J].
CHANG, WH ;
JUANG, DJ ;
LIN, SK ;
HUANG, JD ;
LAM, YWF ;
JANN, MW ;
CHIEN, CP .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1995, 10 (01) :47-51
[5]  
CHANG WH, 1993, PROG NEURO-PSYCHOPH, V17, P105
[6]  
CHANG WH, 1991, J CLIN PSYCHOPHARM, V11, P99
[7]  
CHANG WH, 1993, PSYCHOPHARMACOLOGIA, V106, P289
[8]  
CHOUINARD G, 1984, PSYCHOPHARMACOL BULL, V20, P108
[9]   INTRAMUSCULAR HALOPERIDOL DECANOATE FOR NEUROLEPTIC MAINTENANCE THERAPY - EFFICACY, DOSAGE SCHEDULE AND PLASMA-LEVELS - AN OPEN MULTI-CENTER STUDY [J].
DEBERDT, R ;
ELENS, P ;
BERGHMANS, W ;
HEYKANTS, J ;
WOESTENBORGHS, R ;
DRIESENS, F ;
REYNTJENS, A ;
VANWIJNGAARDEN, I .
ACTA PSYCHIATRICA SCANDINAVICA, 1980, 62 (04) :356-363
[10]   PHARMACOKINETICS AND THERAPEUTIC EFFICACY OF HALOPERIDOL DECANOATE AFTER LOADING DOSE ADMINISTRATION [J].
DECUYPER, H ;
BOLLEN, J ;
VANPRAAG, HM ;
VERSTRAETEN, D .
BRITISH JOURNAL OF PSYCHIATRY, 1986, 148 :560-566